MKI67 and breast cancer: But already, they clearly suggest that patients with Ki67-positive breast cancer potentially derive a high benefit from adjuvant docetaxel (adjusted HR = 0.51), and it might be a candidate for intensifying taxane delivery (six cycles and/or a dose-dense scheme).